Zepbound 2.5 mg is the starting dose of tirzepatide for chronic weight management. According to the FDA label, you take it once weekly for four weeks, then escalate to 5 mg. The starting dose is designed to help the body acclimate to the medication and reduce gastrointestinal side effects, not to deliver maintenance-level weight loss.
What “Zepbound 2.5” Refers To
Zepbound is the brand name for tirzepatide approved by the FDA in November 2023 for chronic weight management in adults with obesity (BMI 30 or higher) or overweight (BMI 27 or higher) with at least one weight-related comorbidity. In 2024, the FDA also approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity.
The medication comes in single-dose prefilled pens at six dose strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. “Zepbound 2.5” simply refers to the 2.5 mg pen, the lowest dose and the standard starting dose. For background on injectable weight management options, our prediabetes treatment hub covers the broader category.
Why the Starting Dose Exists
Tirzepatide activates both GIP and GLP-1 receptors. These pathways slow gastric emptying, reduce appetite, and improve insulin response, but they also commonly cause nausea, vomiting, diarrhea, and constipation. The 2.5 mg starting dose introduces the body to these effects gradually. Per FDA labeling, the 2.5 mg dose is for treatment initiation and is not intended for chronic glycemic or weight-management treatment at this dose alone.
The FDA Titration Schedule
The standard titration schedule from the prescribing information:
| Weeks | Dose | Purpose |
|---|---|---|
| 1-4 | Zepbound 2.5 mg | Starting dose; tolerability |
| 5-8 | 5 mg | First maintenance dose |
| 9-12 | 7.5 mg | Optional escalation |
| 13-16 | 10 mg | Optional escalation; second maintenance option |
| 17-20 | 12.5 mg | Optional escalation |
| 21+ | 15 mg | Highest maintenance dose |
Recommended maintenance doses for weight management are 5 mg, 10 mg, and 15 mg. The 7.5 mg and 12.5 mg doses are bridge doses used when escalation is needed but the next maintenance step is not yet tolerated.
What to Expect on Zepbound 2.5
Weight Loss
Most patients lose a few pounds during the first four weeks on Zepbound 2.5 mg, but the dose is generally too low to produce maintenance-level results. SURMOUNT-1 reported mean weight loss of 15.0%, 19.5%, and 20.9% at the 5 mg, 10 mg, and 15 mg maintenance doses, respectively, over 72 weeks. Early loss on 2.5 mg often reflects appetite suppression and reduced caloric intake.
Side Effects
Common side effects during the 2.5 mg phase:
- Nausea (the most common)
- Diarrhea
- Constipation
- Vomiting
- Decreased appetite
- Abdominal discomfort
- Fatigue
- Burping or reflux
These are generally most intense during the first week after the first injection and improve over the following weeks. Eating smaller meals, stopping before fullness, staying hydrated, and avoiding very greasy or sweet foods can reduce GI symptoms.
When Escalation Is Appropriate
Per the label, escalation from Zepbound 2.5 to 5 mg occurs after four weeks. Reasons your clinician may extend the 2.5 mg phase include:
- Significant ongoing nausea or vomiting
- Dehydration concerns
- Persistent constipation
- Other tolerability issues
Reasons your clinician may not need to escalate aggressively:
- You are losing weight on track at the current dose
- Side effects are well controlled and you prefer to stay lower
- Cost or supply constraints
How to Take Zepbound 2.5
Zepbound is injected subcutaneously once weekly on the same day, with or without food. Approved sites are the abdomen (away from the navel), front of the thigh, or back of the upper arm. Rotate sites weekly. Storage is refrigerated at 36-46 F, with up to 21 days at room temperature up to 86 F if needed.
Contraindications and Warnings
Zepbound carries an FDA boxed warning for thyroid C-cell tumors based on rodent studies. Personal or family history of medullary thyroid carcinoma or MEN 2 are contraindications. Other warnings include pancreatitis, gallbladder disease, hypoglycemia (especially when used with insulin or sulfonylureas), acute kidney injury from dehydration, severe gastrointestinal disease, hypersensitivity, and risk of pulmonary aspiration during anesthesia. Discuss your full medical history with your clinician before starting. For glucose monitoring guidance, see our A1C test guide.
The Bottom Line
Zepbound 2.5 mg is the standard four-week starting dose for tirzepatide weight management. It is designed to acclimate your body to the medication and limit GI side effects, not to deliver maintenance weight loss on its own. Most clinically meaningful loss begins after escalation to 5 mg or higher, and the schedule should always follow the FDA label and your clinician’s instructions.
Medical disclaimer: This article is for educational purposes only and is not medical advice. Always consult your physician or a qualified healthcare provider before starting, stopping, or changing any medication or treatment plan.
